drugset / Trial / NCT00358163
Trial of PTK787/ZK 222584 Plus Paclitaxel
Phase 1
Terminated
7 enrolled
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center · collabBrigham and Women's Hospital · collabMassachusetts General Hospital · collabNovartis Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
PTK787/ZK 222584 is an inhibitor of VEGFR family tyrosine kinases. The primary objective of this study is to assess the safety of daily oral PTK787/ZK 222584 in combination with paclitaxel infused every 21 days. Secondary objectives include pharmacokinetic assessment of the impact of PTK787/ZK 222584 on paclitaxel metabolism and evaluation of tumor response to the investigational treatment.
Timeline
- Start
- 2006-04-26
- Primary completion
- 2008-05-29
- Completion
- 2008-05-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | — | Intravenous |
| Subject | vatalanib | Small molecule | — | Oral |